Ceftolozane-Tazobactam Activity against Phylogenetically Diverse Clostridium difficile Strains | Zendy

Mark D. Gonzalez | Zendy; Meghan A. Wallace | Zendy; Tiffany Hink | Zendy; Erik R. Dubberke | Zendy; CareyAnn D. Burnham | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ceftolozane-Tazobactam Activity against Phylogenetically Diverse Clostridium difficile Strains

Author(s) -

Mark D. Gonzalez,

Meghan A. Wallace,

Tiffany Hink,

Erik R. Dubberke,

CareyAnn D. Burnham

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01670-15

Subject(s) - clostridium difficile , microbiology and biotechnology , tazobactam , anaerobic bacteria , clostridium , bacteria , biology , urinary system , medicine , antibiotics , antibiotic resistance , genetics , imipenem , endocrinology

Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research